Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is starting a new study program — DEM-A22-1 — on Nov. 15, 2022. The study, a first for Lexaria, will evaluate whether LEXX’s DehydraTECH-processed cannabidiol (“CBD”) may have potential for therapeutic treatment for dementia. According to the announcement, Lexaria has previously shown the efficacy of DehydraTECH-CBD in studies focused on human hypertension; the studies showed no serious side effects. Lexaria is exploring the potential for dementia based on previous clinical studies that have established connections between hypertension and dementia: specifically, that individuals who have high blood pressure are more likely to develop vascular dementia, which is the second most common form of dementia following Alzheimer’s disease. The new study is a dose-ranging, two-month program evaluating a total of 32 Long Evans rats, which will receive DehydraTECH-CBD. The study will be conducted by a Canada-based, leading, third-party testing lab and is scheduled to be complete by end of January 2023. Additional studies may follow, depending on the results of this first program. Lexaria will provide updates from this study as they become available.
To view the full press release, visit https://ibn.fm/v9Ozy
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.